The Opportunity Unveiled
LOS ANGELES, Oct. 2, 2024 — The stage is set for ALLR investors to step into the driver’s seat regarding the securities legal battle involving Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ticker symbol ALLR.
Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024
The case alleges that, during the Class Period, it was shielded from investors that: (1) The Dovitinib NDA’s regulatory prospects were exaggerated by Defendants; (2) Allarity and three former officers were complicit in wrongful conduct concerning the Dovitinib NDA and/or the Dovitinib-DRP PMA; (3) This behavior exposed the company to heightened regulatory and government scrutiny and possible legal repercussions; (4) Upon revealing that it was under investigation for wrongdoing related to the Dovitinib NDA and/or the Dovitinib-DRP PMA, the company downplayed the risks of enforcement action; and (5) Consequently, the Company’s optimistic statements about its business were significantly misleading and lacked a reasonable foundation throughout.
As the scene unfolds, investors are encouraged to keep a close eye on updates via Twitter: twitter.com/FRC_LAW.
Joining the class action requires no immediate action; you can opt to seek counsel or remain a passive participant. For more information or inquiries on this litigation, reach out to Frank R. Cruz at his firm in Century City, California.
With this intriguing development in motion, stay tuned to witness the unfolding drama. Will justice be served? Only time will tell.
If you’re a shareholder who suffered a loss, seize this moment to participate in reshaping the narrative. The allure of legal proceedings beckons. Take a stand or stay in the shadows; the choice is yours, dear investor.
